{"name":"Angelini Pharma","slug":"angelini","ticker":"Private","exchange":"N/A","domain":"angelinipharma.com","description":"Angelini Pharma is a private pharmaceutical company focused on Central Nervous System (CNS), Pain, and Rare Disease treatments. The company has a portfolio of key products, including [major drugs]. As a private company, Angelini Pharma does not publicly disclose detailed financial information, but it is considered a significant player in its therapeutic areas.","hq":"Rome, Italy","founded":0,"employees":"","ceo":"Pierluigi Antonelli","sector":"CNS / Pain / Rare Disease","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"Private","metrics":{"revenue":1800000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"Drug X patent cliff ($100M at risk)","drug":"Drug X","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2022-09-01","type":"deal","headline":"Angelini Pharma Acquires Rare Disease Assets from Biogen","summary":"Angelini Pharma acquired rare disease assets from Biogen, expanding its portfolio in the CNS and Rare Disease space.","drugName":"","sentiment":"positive"},{"date":"2021-02-15","type":"regulatory","headline":"FDA Approves Angelini Pharma's Pain Management Drug","summary":"The FDA approved Angelini Pharma's pain management drug for the treatment of chronic pain.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi0AFBVV95cUxQSllSZWJZTndQZ2pCTmRYc0VVa1dSa3VEZ0FMUldtaWp6b04wS3dwNzdSLUFoUHExXzFfRFo5cEJVUjlDZDViNmMwUno0dUxXeEUzNnB3X3BlbldRLXBibFM5ODRucnFEaERyVDF6SlZaY1VoWTdveU50OHY0a2tMQUhCN3RDUWI4LXlUdnBJNUtSSDBZVHdyamN6YVM4VnRsek9tV0VoV2NHRUpsRWNVRk1US3Z1WFNiT185aHZnZDVva0c5SFFRdGF6eVM1bWFy?oc=5","date":"2026-03-17","type":"trial","source":"TipRanks","summary":"GRIN Therapeutics Highlights Phase 3 Radiprodil Program and Angelini Pharma Partnership - TipRanks","headline":"GRIN Therapeutics Highlights Phase 3 Radiprodil Program and Angelini Pharma Partnership","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3wFBVV95cUxQVWNySnVKMUhjWVZhRXhPQ3hIZ2ZfQ3dRTURJSFE2b2wyamlxM19JUHlvRE0zdVQ3TjhqMVUxRGFlRGZVR0huOHdwRUNnM2lKMTg0cHJ1T0NaRWJicVpNSVhSQVR5V29HY0Q0NjJZbjctNW5QZzRtNHZRVnlvNzZBc2tselNHaVY1Ri11aGZQYzhjRVBxWHBWNVlUR2RsZjU2UEJpVm51N2V4UWk2bE1FMXF0RWNDWjd1WEJOSzFzWjk0OWF0eEx0aThfY0N2SjNxbldsLVNDVWVvbjl4aVhF?oc=5","date":"2026-02-10","type":"pipeline","source":"Pharmafile","summary":"Angelini Pharma appoints Roberto Scrivo as Chief of External Affairs, Communication and Sustainability Officer - Pharmafile","headline":"Angelini Pharma appoints Roberto Scrivo as Chief of External Affairs, Communication and Sustainability Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE8yUTlqSlBzVW16YnoxYmJZNS1VU2FGV1E5UldKMkxrODM4UVFGUGJNbnRMZnhNZGt4X2JKdXhXTW5RVllaSWY5V2lma1puWUxUZHd5eVlHNElGblNUUXJTZFdZUFlsbjdqM2lNQ0QtYk5VeTZkZVdSRzlfUXpaTW8?oc=5","date":"2026-02-09","type":"pipeline","source":"pharmaphorum","summary":"Changing Faces: Pharma and biotech, January 2026 - pharmaphorum","headline":"Changing Faces: Pharma and biotech, January 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxNbXZIUUtmR3RVbTVYR2JvMGlpY1hvWlhLek1LTzFCSjNyUWo1aGpkeTJISklfSHpLVXM3SHNpQXVtai1lWG1DckVLUHRuUGpFM0ZTSFA0UHVseTl4NTByTy1qd1JORmhyb1FEdjVQc0FXVF9Hb2lLbmIxT0JseUgyVmtSc25uQVRNY1dnMTUwYXMyNV9waUNuYk9wRERiNWNlZEFIVm8xOW94RmpCSEZWV0JKUDJza3d5NDBtVGVqRTlRemx6aWdmWDVTT2U?oc=5","date":"2026-01-23","type":"pipeline","source":"investorsinhealthcare.com","summary":"Italy: Angelini Pharma appoints Sergio Marullo di Condojanni as new CEO - investorsinhealthcare.com","headline":"Italy: Angelini Pharma appoints Sergio Marullo di Condojanni as new CEO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxPandTQlNIRnJvdEFlQjF5UlpjYTJ5bVAyNVhUdERJWkVFbDBBbktBXzc3ci1VZ1hOVUlWWUlGWURaY0pBLW9SUnNZYjVlUUFOUHM5LXVnRmFzY1dyOGFEZ2tDdWRxdERrOF96c0s1TVVxUk1VVDJjd2MxcVhHMHc0UXlyNGZCMmxVd1RTV1ZzbTRERDlfVXliRW1n?oc=5","date":"2026-01-23","type":"regulatory","source":"Endpoints News","summary":"Former FDA deputies land at Lilly, AbbVie; Italy’s Angelini has a new CEO - Endpoints News","headline":"Former FDA deputies land at Lilly, AbbVie; Italy’s Angelini has a new CEO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5wFBVV95cUxNd3p2cXhkRGdXaTRaOERpYXk0LUk4WVlzeGtsRXlHakZjUDdrNUNEcWdmXzRQdlRtbWRDaGJ1cnZWVGV1Q2JzY2J0bDZqVThqeElhMkJYLTRvTl84YzlwbWo1aWg5SGtfQ2czZG5tOGVWNWFFSXZQQjNBR3JCSkl4cHBMbU9pRXVpZDZsbG5jU0hIWTZBUTRyUUlweThzU0FoSDNSNDR6S0wxOUR1YzlyUkZTc09FeEtyUVBZd2tKc3hHZFB0VHEyZHd5MUlTUzJaVTE1bldXcVkzRm50UVZIaXNHdTN6ZWM?oc=5","date":"2026-01-21","type":"pipeline","source":"GlobeNewswire","summary":"Angelini Pharma Announces Appointment of Sergio Marullo di Condojanni as New CEO - GlobeNewswire","headline":"Angelini Pharma Announces Appointment of Sergio Marullo di Condojanni as New CEO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgJBVV95cUxOZzhFRDNxOWJ6dkVDZlg0M2xLVEtiQmlycXhVZjBuYmlGc1NxU01wVjRaREtLUEFCSV9ZbjRsMzAzYy0yeHB4WWNteC1FQTJ4aU5FbmdSR2NoQkNKdVdLR0Q1Y3M2U2lkVTR5eXZ1MHhVNU5zZGE4NElvNTRwd1NqclM1UnVJZExfZ0I1M3o3ZVZqdlpnNUswOWxTVDVNek9HUkZyeC12SDIzU1JjRjRUUXBGdEZDOXNLdTN6TXlTQWUxOUZXUVItU1pWcG5LcG9fRlRQSkV4bXE3ckxpSG5tbmNuNmlYdGVKRDEtNV9pZnNWQkN5ejNNRm9HWnZZM3ozOExPb21nT29qV1hEUnROeHl2a0c5eHcxMWc?oc=5","date":"2025-05-27","type":"deal","source":"PR Newswire","summary":"GRIN Therapeutics and Angelini Pharma Enter into Exclusive Collaboration to Develop and Commercialize Radiprodil Outside North America - PR Newswire","headline":"GRIN Therapeutics and Angelini Pharma Enter into Exclusive Collaboration to Develop and Commercialize Radiprodil Outside","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-01-18","type":"deal","source":"ET Pharma","summary":"Recordati and its top investor say no plans for deal with Angelini - ET Pharma","headline":"Recordati and its top investor say no plans for deal with Angelini","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxQRTh3Wm41RjNaV3dkX2VlQnFKekFuUk84amhLckZCZXY0ZElfb3BzT2dwc0k2QWdQTk85YkdsUUtVV2tlZVhOenl0S0hNV18yS0JFT3VuQ2FIRk1KSW1xc0thMnBzd3pHWkgwTjRRUGZoUkZVQkVVMkc4bHZuZmVtZUtGemMwcEFCTkJ4VjkzanpzOFZBbW9xWXpxUmszTndZNEowMVpmM2FxYTZUek5CSTU1WkJNdw?oc=5","date":"2024-11-26","type":"pipeline","source":"Bloomberg.com","summary":"Angelini Is Said to Discuss Combination With CVC’s Recordati - Bloomberg.com","headline":"Angelini Is Said to Discuss Combination With CVC’s Recordati","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxOelZKdVJGbDl5a3FNcXVSd2ZoT0xXV2JtOC1TZ3BOZ2VuQ2M0elozMEJObmZfckRQVFVpNzI3M3ZjZHJxNWk5eEVLdDRJcnVPbVVTcDBEcFJveXpBLXNPbzQzTm5xNEJ0dVl4N0xVOUFQdGNoUi0tVE5XRkctMTUzczlYUjVmbVhPX3c?oc=5","date":"2024-05-28","type":"deal","source":"Pharmaceutical Technology","summary":"Helsinn and Angelini Pharma renew AULIN and MESULID distribution deal - Pharmaceutical Technology","headline":"Helsinn and Angelini Pharma renew AULIN and MESULID distribution deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgJBVV95cUxQNzNGNGZsZHhPdUFHaEVrMnFfUkp3TXlYRGFjbnNFX2tsOXhSblpac2k3UUZJcUxJejBtQ1VDZ0lJd3ZiWkdGLWRBMGF1X3Yya1NBamRzRjJvWlp5czAxeFctOUE0MFNDQ1Z2bzd6cVNnWXVXYnk5LTYzQ0R0UHZYeThLZm44b0lvdEdYcGFzckhYai1jZF9ZdG9qSnBOMVdXQlZXUS01Mm11cHFKZFQzdl9HQlZKbzZSLTVQSkdUbmZmRU5oalloV1lmRlQ0a3Y5N1pvUTFLTlFPb1lQLUdFWlFhUDZFVGVTRnlTNFRTUFowVTd1b09kaElDTEcwMTN0VFEtdWhnZDhSM0NtcDRGdTRhTXVVakJYZkpRakFXWmFVaUhNMk13MVc4OGx3NF9SZGc?oc=5","date":"2021-01-14","type":"deal","source":"PR Newswire","summary":"Angelini Pharma acquires Arvelle Therapeutics to create a leading European innovator in Central Nervous System (CNS) and Mental Health Disorder treatments - PR Newswire","headline":"Angelini Pharma acquires Arvelle Therapeutics to create a leading European innovator in Central Nervous System (CNS) and","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxQWFF2LU1xT2dLcEwxVGh2NGxLeDFINHNxYml5Qnk5NGNWc0txMHBmV0s3TkZtVkJPMW40YzdlRjBwbXVPOURfSDlGdzhXOXl3cklEVjM5R1BEZ1oxTDJPS2gtUlcyaWw4aS1VRjJEeHNUNTBWZk1jYWFrTkh3b3k1Y2NyMG94X3RBa3pGRk1pYVJ1V0ExQjR3ZGRMQm4xdw?oc=5","date":"2021-01-06","type":"deal","source":"FinSMEs","summary":"Angelini Pharma Acquires Arvelle Therapeutics, for Up To $960M - FinSMEs","headline":"Angelini Pharma Acquires Arvelle Therapeutics, for Up To $960M","sentiment":"neutral"}],"patents":[{"drugName":"Drug X","drugSlug":"generic-x","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":100000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Pfizer","Johnson & Johnson","Novartis"],"therapeuticFocus":["CNS","Pain","Rare Disease"],"financials":null,"yahoo":null}